Related Experiment Videos
Current issues with blood transfusions in sickle cell disease.
1Department of Pediatrics, University of California, San Francisco, USA.
Seminars in Hematology
|February 24, 2001
Summary
Blood transfusions are vital for sickle cell disease patients but carry risks. Using leukocyte-reduced, antigen-matched blood and careful monitoring minimizes complications like alloimmunization and infections.
Area of Science:
- Hematology
- Transfusion Medicine
Background:
- Sickle cell disease (SCD) causes significant morbidity.
- Transfusion therapy is increasingly used for SCD complications.
- Understanding transfusion risks is crucial for patient safety.
Purpose of the Study:
- To review blood component therapy for sickle cell patients.
- To highlight the associated risks and benefits.
- To provide recommendations for safer transfusion practices.
Main Methods:
- Review of current literature on blood component therapy in SCD.
- Analysis of transfusion risks including infections, alloimmunization, and adverse events.
- Evaluation of strategies to mitigate transfusion-related complications.
Main Results:
- Leukocyte-reduced packed red cells are preferred.
- Transfusion-acquired infections and alloimmunization remain significant risks.
- Phenotypic matching for antigens (E, C, K) reduces alloimmunization.
- Transfusions can trigger SCD events; careful monitoring and diuretic therapy are recommended.
Conclusions:
- Transfusion therapy is essential but carries inherent risks.
- Leukocyte reduction and phenotypic matching are standard of care.
- Close patient monitoring during transfusions is critical for safety.